Abstract: Multi-compartment patches containing skin-permeable forms of pharmaceutically effective amounts of an opioid agonist, an NMDA receptor antagonist and an anti-inflammatory are useful for the transdermal delivery of the active ingredients to alleviate pain.

Abstract: The present invention is drawn to a transdermal patch for the delivery of a nitroglycerin or other NO donor. The patch can comprise a backing layer, and a nitroglycerin-containing composition or other NO donor-containing composition which is supported at least in part by the backing layer. The transdermal patch can have a drug delivery zone defined by the area where the composition contacts an intact human skin site, and the transdermal patch can be formulated to deliver a nitric oxide donor, such as nitroglycerin, at from about 5 ?g/hour to about 70 ?g/hour. In one embodiment, the transdermal patch can provide a delivery rate at the drug delivery zone of from about 1 ?g/cm2/day to about 600 ?g/cm2/day. In another embodiment, the transdermal patch can contain from 6 wt % to 18 wt % of the nitric oxide donor, e.g., nitroglycerin. In each embodiment, the patch can contain at least 450 ?g/cm2 of nitroglycerin.

Abstract: A system and method for treating damaged musculoskeletal tissue includes an orthopedic support structure and a nitroglycerin-containing composition. The orthopedic support structure provides mechanical support to the damaged tissue and maintains the nitroglycerin-containing composition in contact with the skin of a subject wearing using the system. The nitroglycerin-containing composition can be integrated into the orthopedic support structure or the support structure can be configured to contain removable doses of the nitroglycerin-containing composition. The system and method provides relief of pain and improved function of the musculoskeletal tissue.

Abstract: The present invention provides methods for treating tendinopathy in the absence of inflammation by the transdermal administration of nitroglycerin. Such methods include methods for relieving pain associated with such tendinopathies, and the use of a transdermal patch configured to deliver glyceryl trinitrate at a rate of 5 mcg/hr to about 85 mcg/hr.

Abstract: A method for delivery of substance through at least one dermal layer, by providing a substance in microcapsules at a predetermined size, within a medium (150) for holding the microcapsules; placing the medium for holding the microcapsules on a surface of a patch (100) adjacent the skin (320) of a human or animal; and applying energy (200) to the patch, the energy having a characteristic of disturbing the integrity of the microcapsules, thereby resulting in release of the substance from the microcapsules. The energy may be selectively applied to release the substance at desired times. The substance may be a drug or other active agent.

Abstract: An apparatus for performing in-vivo sonoporation of a skin area and transdermal and/or intradermal delivery of a drug solution includes a container having an end adjacent the skin area and containing the drug solution. The container further includes an ultrasound horn having a tip submerged in the drug solution for applying ultrasound radiation to the drug solution. The ultrasound radiation has a frequency in the range of 15 KHz and 1 MHz and is applied at an intensity, for a period of time and at a distance from said skin area effective to generate cavitation bubbles. The cavitation bubbles collapse and transfer their energy into the skin area, thus causing the formation of pores in the skin area. The ultrasound radiation intensity and distance from the skin area are also effective in generating ultrasonic jets, which ultrasonic jets then drive the drug solution through the end adjacent the skin area and the formed pores into the skin.

Abstract: An apparatus for performing in-vivo sonoporation of a skin area and transdermal and/or intradermal delivery of a drug solution includes a container having an end adjacent the skin area and containing the drug solution. The container further includes an ultrasound horn having a tip submerged in the drug solution for applying ultrasound radiation to the drug solution. The ultrasound radiation has a frequency in the range of 15 KHz and 1 MHz and is applied at an intensity, for a period of time and at a distance from said skin area effective to generate cavitation bubbles. The cavitation bubbles collapse and transfer their energy into the skin area, thus causing the formation of pores in the skin area. The ultrasound radiation intensity and distance from the skin area are also effective in generating ultrasonic jets, which ultrasonic jets then drive the drug solution through the end adjacent the skin area and the formed pores into the skin.

Abstract: An apparatus for performing in-vivo sonoporation of a skin area and transdermal and/or intradermal delivery of a drug solution includes a container having an end covered with a porous membrane and containing the drug solution and an ultrasound horn having a tip submerged in the drug solution. The ultrasound horn applies ultrasound radiation to the drug solution. The ultrasound radiation has a frequency in the range of 15 KHz and 1 MHz and is applied at an intensity, for a period of time and at a distance from said skin area effective to generate cavitation bubbles. The cavitation bubbles collapse and transfer their energy into the skin area thus causing the formation of pores in the skin area. The ultrasound radiation intensity and distance from the skin area are also effective in generating ultrasonic jets, which ultrasonic jets then drive the drug solution through the porous membrane and the formed pores into the skin.